APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Japanese Encephalitis Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Live Attenuated Japanese Encephalitis Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchLive Attenuated Japanese Encephalitis Vaccine Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Japanese Encephalitis Vaccine Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Live Attenuated Japanese Encephalitis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Japanese Encephalitis Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Japanese Encephalitis Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Live Attenuated Japanese Encephalitis Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Live Attenuated Japanese Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Japanese Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Japanese Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Live Attenuated Japanese Encephalitis Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Live Attenuated Japanese Encephalitis Vaccine market include Wuhan Institute of Biological Products, Sanofi, Novartis, Lanzhou Institute of Biological Products, Chengdu Institute of Biological Products, Cheng Da Biology, Beijing Temple of Heaven Biological Products, Valneva and Glovax Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live Attenuated Japanese Encephalitis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Attenuated Japanese Encephalitis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Attenuated Japanese Encephalitis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Japanese Encephalitis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Attenuated Japanese Encephalitis Vaccine Segment by Company

Wuhan Institute of Biological Products

Sanofi

Novartis

Lanzhou Institute of Biological Products

Chengdu Institute of Biological Products

Cheng Da Biology

Beijing Temple of Heaven Biological Products

Valneva

Glovax Co., Ltd.

Biocelect Pty Ltd

Bharat Biotech

Live Attenuated Japanese Encephalitis Vaccine Segment by Type

2.5ml

1ml

0.5ml

Live Attenuated Japanese Encephalitis Vaccine Segment by Application

Hospital

Clinic

Live Attenuated Japanese Encephalitis Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Live Attenuated Japanese Encephalitis Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Live Attenuated Japanese Encephalitis Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Live Attenuated Japanese Encephalitis Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Live Attenuated Japanese Encephalitis Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Japanese Encephalitis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Japanese Encephalitis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Japanese Encephalitis Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Japanese Encephalitis Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Attenuated Japanese Encephalitis Vaccine industry.

Chapter 3: Detailed analysis of Live Attenuated Japanese Encephalitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Live Attenuated Japanese Encephalitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Live Attenuated Japanese Encephalitis Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Live Attenuated Japanese Encephalitis Vaccine Industry Trends Table 2. Live Attenuated Japanese Encephalitis Vaccine Industry Drivers Table 3. Live Attenuated Japanese Encephalitis Vaccine Industry Opportunities and Challenges Table 4. Live Attenuated Japanese Encephalitis Vaccine Industry Restraints Table 5. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Company (2021-2026) Table 7. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Live Attenuated Japanese Encephalitis Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Live Attenuated Japanese Encephalitis Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Live Attenuated Japanese Encephalitis Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Live Attenuated Japanese Encephalitis Vaccine Company, Product Type & Application Table 13. Global Live Attenuated Japanese Encephalitis Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Live Attenuated Japanese Encephalitis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 2.5ml Table 18. Significant Companies of 1ml Table 19. Significant Companies of 0.5ml Table 20. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2021-2026) & (k units) Table 22. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2027-2032) & (k units) Table 23. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Type (2021-2026) Table 24. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Type (2027-2032) Table 25. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type (2021-2026) Table 29. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2021-2026) & (k units) Table 34. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2027-2032) & (k units) Table 35. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region (2021-2026) & (k units) Table 44. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region (2027-2032) & (k units) Table 46. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Live Attenuated Japanese Encephalitis Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Live Attenuated Japanese Encephalitis Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2026) & (k units) Table 57. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2027-2032) & (k units) Table 59. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Market Share by Country (2027-2032) Table 64. Wuhan Institute of Biological Products Company Information Table 65. Wuhan Institute of Biological Products Business Overview Table 66. Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 68. Wuhan Institute of Biological Products Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Sanofi Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 73. Sanofi Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Novartis Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 78. Novartis Recent Development Table 79. Lanzhou Institute of Biological Products Company Information Table 80. Lanzhou Institute of Biological Products Business Overview Table 81. Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 83. Lanzhou Institute of Biological Products Recent Development Table 84. Chengdu Institute of Biological Products Company Information Table 85. Chengdu Institute of Biological Products Business Overview Table 86. Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 88. Chengdu Institute of Biological Products Recent Development Table 89. Cheng Da Biology Company Information Table 90. Cheng Da Biology Business Overview Table 91. Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 93. Cheng Da Biology Recent Development Table 94. Beijing Temple of Heaven Biological Products Company Information Table 95. Beijing Temple of Heaven Biological Products Business Overview Table 96. Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 98. Beijing Temple of Heaven Biological Products Recent Development Table 99. Valneva Company Information Table 100. Valneva Business Overview Table 101. Valneva Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Valneva Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 103. Valneva Recent Development Table 104. Glovax Co., Ltd. Company Information Table 105. Glovax Co., Ltd. Business Overview Table 106. Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 108. Glovax Co., Ltd. Recent Development Table 109. Biocelect Pty Ltd Company Information Table 110. Biocelect Pty Ltd Business Overview Table 111. Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 113. Biocelect Pty Ltd Recent Development Table 114. Bharat Biotech Company Information Table 115. Bharat Biotech Business Overview Table 116. Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 118. Bharat Biotech Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Live Attenuated Japanese Encephalitis Vaccine Distributors List Table 122. Live Attenuated Japanese Encephalitis Vaccine Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Live Attenuated Japanese Encephalitis Vaccine Product Image Figure 2. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Japanese Encephalitis Vaccine Sales (2021-2032) & (k units) Figure 5. Global Live Attenuated Japanese Encephalitis Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Live Attenuated Japanese Encephalitis Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 2.5ml Image Figure 10. 1ml Image Figure 11. 0.5ml Image Figure 12. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Type (2021-2032) Figure 15. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Live Attenuated Japanese Encephalitis Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Live Attenuated Japanese Encephalitis Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 2.5ml
  • 1ml
  • 0.5ml
Applications
  • Hospital
  • Clinic
Companies covered
  • Wuhan Institute of Biological Products
  • Sanofi
  • Novartis
  • Lanzhou Institute of Biological Products
  • Chengdu Institute of Biological Products
  • Cheng Da Biology
  • Beijing Temple of Heaven Biological Products
  • Valneva
  • Glovax Co., Ltd.
  • Biocelect Pty Ltd
  • Bharat Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Live Attenuated Japanese Encephalitis Vaccine Market Dynamics
  1. 2.1 Live Attenuated Japanese Encephalitis Vaccine Industry Trends
  2. 2.2 Live Attenuated Japanese Encephalitis Vaccine Industry Drivers
  3. 2.3 Live Attenuated Japanese Encephalitis Vaccine Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Japanese Encephalitis Vaccine Industry Restraints
3 Live Attenuated Japanese Encephalitis Vaccine Market by Company
  1. 3.1 Global Live Attenuated Japanese Encephalitis Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Live Attenuated Japanese Encephalitis Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Live Attenuated Japanese Encephalitis Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Live Attenuated Japanese Encephalitis Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Live Attenuated Japanese Encephalitis Vaccine Company Product Type and Application
  8. 3.8 Global Live Attenuated Japanese Encephalitis Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Live Attenuated Japanese Encephalitis Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Live Attenuated Japanese Encephalitis Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Live Attenuated Japanese Encephalitis Vaccine Market by Type
  1. 4.1 Live Attenuated Japanese Encephalitis Vaccine Type Introduction
  2. 4.1.1 2.5ml
  3. 4.1.2 1ml
  4. 4.1.3 0.5ml
  5. 4.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type
  6. 4.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type
  10. 4.3.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type (2021-2032)
5 Live Attenuated Japanese Encephalitis Vaccine Market by Application
  1. 5.1 Live Attenuated Japanese Encephalitis Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application
  5. 5.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application
  9. 5.3.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application (2021-2032)
6 Live Attenuated Japanese Encephalitis Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Live Attenuated Japanese Encephalitis Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Country, 2025 VS 2032
7 Live Attenuated Japanese Encephalitis Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Live Attenuated Japanese Encephalitis Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Live Attenuated Japanese Encephalitis Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Wuhan Institute of Biological Products
  2. 8.1.1 Wuhan Institute of Biological Products Company Information
  3. 8.1.2 Wuhan Institute of Biological Products Business Overview
  4. 8.1.3 Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  6. 8.1.5 Wuhan Institute of Biological Products Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Lanzhou Institute of Biological Products
  20. 8.4.1 Lanzhou Institute of Biological Products Company Information
  21. 8.4.2 Lanzhou Institute of Biological Products Business Overview
  22. 8.4.3 Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  24. 8.4.5 Lanzhou Institute of Biological Products Recent Developments
  25. 8.5 Chengdu Institute of Biological Products
  26. 8.5.1 Chengdu Institute of Biological Products Company Information
  27. 8.5.2 Chengdu Institute of Biological Products Business Overview
  28. 8.5.3 Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  30. 8.5.5 Chengdu Institute of Biological Products Recent Developments
  31. 8.6 Cheng Da Biology
  32. 8.6.1 Cheng Da Biology Company Information
  33. 8.6.2 Cheng Da Biology Business Overview
  34. 8.6.3 Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  36. 8.6.5 Cheng Da Biology Recent Developments
  37. 8.7 Beijing Temple of Heaven Biological Products
  38. 8.7.1 Beijing Temple of Heaven Biological Products Company Information
  39. 8.7.2 Beijing Temple of Heaven Biological Products Business Overview
  40. 8.7.3 Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  42. 8.7.5 Beijing Temple of Heaven Biological Products Recent Developments
  43. 8.8 Valneva
  44. 8.8.1 Valneva Company Information
  45. 8.8.2 Valneva Business Overview
  46. 8.8.3 Valneva Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Valneva Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  48. 8.8.5 Valneva Recent Developments
  49. 8.9 Glovax Co., Ltd.
  50. 8.9.1 Glovax Co., Ltd. Company Information
  51. 8.9.2 Glovax Co., Ltd. Business Overview
  52. 8.9.3 Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  54. 8.9.5 Glovax Co., Ltd. Recent Developments
  55. 8.10 Biocelect Pty Ltd
  56. 8.10.1 Biocelect Pty Ltd Company Information
  57. 8.10.2 Biocelect Pty Ltd Business Overview
  58. 8.10.3 Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  60. 8.10.5 Biocelect Pty Ltd Recent Developments
  61. 8.11 Bharat Biotech
  62. 8.11.1 Bharat Biotech Company Information
  63. 8.11.2 Bharat Biotech Business Overview
  64. 8.11.3 Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  66. 8.11.5 Bharat Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live Attenuated Japanese Encephalitis Vaccine Value Chain Analysis
  2. 9.1.1 Live Attenuated Japanese Encephalitis Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live Attenuated Japanese Encephalitis Vaccine Sales Mode & Process
  6. 9.2 Live Attenuated Japanese Encephalitis Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live Attenuated Japanese Encephalitis Vaccine Distributors
  9. 9.2.3 Live Attenuated Japanese Encephalitis Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst